MarketInOut Stock Screener Log In | Sign Up
 

Kymera Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 06/26/2026 16:00
Kymera Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization9,654.57 mln
Float55.03 mln
Earnings Date07/31/2026

Piotroski F-Score

3 / 9
Below average

Beneish M-Score

-3.39
Reliable

1-Year Forecast

119
Modest upside

Relative Strength

98 / 100
Top performer

Debt / Equity

0.05
Debt-free

ROE

-27.05
Deeply negative

Business Description

Kymera Therapeutics is a clinical-stage drug development company founded in 2015 and based in Watertown, Massachusetts. The company creates oral medicines that work by directing the body's own waste-disposal system to eliminate proteins that drive disease. Its pipeline targets conditions ranging from skin and lung diseases to autoimmune disorders and cancer, with several candidates already in human trials. Kymera also partners with Sanofi to advance one of its key programs in immunology and inflammation.

Key Fundamentals

EPS-3.58
ROE-27.05
RPS0.56
ROIC-51.86
ROA-24.00
EBITDA, mln-306
EV / EBITDA-19.91
EV / EBIT-19.38
Revenue, mln51.47
EV / Revenue118

Financial Strength

Altman Z-Score30.04
Piotroski F-Score 3 / 9
Beneish M-Score-3.39
1-Year Target Price119
Short Ratio19.79
Short % of Float15.85

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 19.56% 97 / 100   
1 Month 32.34% 96 / 100   
2 Months 35.88% 89 / 100   
6 Months 29.44% 86 / 100   
1 Year 133% 94 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us